Services for

professionals

In ADNTRO one of our main goals is to contribute to the knowledge of DNA and genetics applied to health. Therefore, we offer massive sequencing services, bioinformatics analysis and disease prevention studies by calculating the polygenic risk (PRS).

NEXT-GENERATION sequencing

100% genome sequencing

Bioinformatics Analysis

Genome analysis and interpretation

PREVENTION

Identifies polygenic risk associated with common diseases

DNA genetic test

Next-generation sequencing

Whole Exome (WES) and Whole Genome (WGS)

The study can be performed with a simple saliva sample to sequence 100% of the genome. Our laboratory will be in charge of extracting and sequencing the DNA.

Genetic results are obtained with high coverage and quality. Possibility of directly requesting exome and/or genome study to particulars.

What does WES and WGS study include?

Your entire genome will be available for life

Explore the genome

Download VCF, BAM and FastQ files with all genetic information, ready for variant analysis and variant prioritization in the clinical context.

ADNTRO'S FULL REPORT

Possibility to access to all ADNTRO report sections with the maximum precision and GWAS studies: health, pharmacogenetics, origins, nutrigenetics, sport, personality and labs.

Ready for diagnostics

Our exome or whole genome sequencing data are of the highest quality and can be used by physicians, clinical geneticists and genetic counselors in the clinical context.

GENETIC CONSULTATION

We offer the possibility (with an additional cost) to receive consultation and advice from our genetic and bioinformatics team to help with any questions about these results.

What technology do we offer?

At ADNTRO we offer different options for DNA analysis depending on the needs and we offer advice during the process, including genetic diagnosis.

Popular

Whole Genome (30x)

950
  • 🔹100% DNA sequencing.
  • 🔹23,000 Genes
  • 🔹Access to ADNTRO reports +1 year of updates
  • 🔹Quality report
  • 🔹File delivery detailed
  • 🔹Ready for diagnosis (30x average coverage)

Whole Exome (150x)

On Request
  • 🔹100% exome sequencing
  • 🔹23,000 Genes - All variants of your genes.
  • 🔹Possibility to study virtual gene windows (virtual gene panels).
  • 🔹Detailed file delivery
  • 🔹Quality report
  • 🔹Ready for diagnosis (150x average coverage).

Full report

We send a full detailed report with the results of the exome and/or genome sequencing including an analysis of the quality parameters.

Possibility of access to the ADNTRO online platform, including all reports calculated from the genome.

Custom graphics

Customized graphs can be prepared with the summary of whole genome sequencing results.

Frequently asked questions

Genotyping analyzes those variants of our genome that are polymorphic, that is, they show great variability between people and are very common in general (> 1% in the population). Genetic association studies (GWAS) are fundamentally based on this type of analysis and help to determine our predisposition to different diseases as well as phenotypic variations in individuals.

Genotyping techniques analyze approximately 700,000 positions in our DNA; compared, whole genome analysis (WGS), in which all your DNA is analyzed (the three billion base pairs) and therefore allows the detection of rare variants in the population. These rare variants tend to have a high impact on the development of diseases and susceptibilities and responses to them. This is the most commonly used genetic research technique in the world.

Firstly, our Home Kit comes at a cheaper price.

With these microarray kits, we perform genotyping, whereby approximately 700,000 positions of your DNA are read. This is sufficient for understanding some common traits, but it cannot be used for diagnosis or detection of rare variants.

Our own comparative studies between 4x and 30x show a quality level difference of over 90%. This applies particularly to differences in those regions and variants that are more difficult to detect - these can only be determined with 30x.

First, we at ADNTRO send a kit to your home for collecting a DNA sample (a simple saliva sample, 2ml). The delivery to your home, as well as the return of the sample to the laboratory, is included in the price.

From the arrival at the laboratory of your test (approx. 5 business days in Europe), your results will be ready in 4 weeks.

You can access your results online, explore all sections of ADNTRO (including health and pharmacogenetics) and download files with your genetic information.

A genetic consultation with a professional team certified by the European Union in molecular genetics is available. As well as by the ADNTRO bioinformatics team. The consultation will be via email. You can query any doubts regarding your results and we will help you in every way necessary.

No clinical diagnosis is offered. For this, you should consult with your doctor

If you decide to have an exome or genome test, we will offer targeted analysis of variants detected in a specific subset of genes. You can contact us by filling out this contact form for more details.

We will give you several formats so you can explore your DNA.

For the WGS High-Pass you will receive:

  • FASTQ
  • BAM and BAI
  • VCF SNP
  • VCF CNV
  • VCF INDEL
  • Others: XLS, PDF of reports, ...
  • Bonus: Circus Plot
  • Diagnostic report (contracted separately)

For the WGS Low-pass:

Differences between virtual panels, exome (WES) and whole genome (WGS)

spanish genome
DNA genetic test

Bioinformatics Analysis Service

Next-generation sequencing genomic data analysis, such as panels, exome and genome, in a fast and efficient way, applying variant priorization tools, ADNTRO algorithms for the interpretation of variants with clinical implications and the possibility of performing genetic reports by expert in human genetics by using international guidelines for variant classification.  

Analysis

Data analysis and variant filtering of VCF, BAM files

Preparation

Preparation of data for final report

CLASIFICATION

Classification and clinical interpretation of variants according to international guidelines (ACMG/AMP)

somatic-germinal

Analysis of somatic-germline sample in cancer

Prioritization

Variant prioritization and selection of candidate variants from exome and whole genome data.

CNVs and SVs

Copy Number Variations (CNVs) and Structural Variants (SVs) can be analyzed.

Clinical pharmacogenetics

Clinical recommendations for drugs (following the CPIC recommendations)

*Possibility of contracting the service of genetic analysis or diagnosis of a clinical suspicion based on sequencing data.
(Not included in the initial price)

Example

Applicable with files from gene, exome (WES) and genome (WGS) panels obtained from ADNTRO or another laboratory, with the possibility of data reanalysis.

Prevention Service

DETECTION

Application of Polygenic Risk Score (PRS) algorithms for the detection of genetic risk of common diseases.

IDENTIFICATION

GWAS studies in large cohorts to identify biomarkers of association.

R&D

Participation in research projects, some examples: Challenges-collaboration, Horizon2030, EIT Health, BIOIB, Genotypia.

Example

Polygenic risk analysis based on SNP-Arrays (genotyping) and NGS for better diagnosis and treatment of common and complex diseases.

More than 120 complex diseases based on GWAS studies.

Collaborators

Research area

ADNTRO collaborates with several national and international projects in genomic medicine and is part of several consortiums and clusters, as well as with research entities such as UKBiobank, AseBio or Barcelona Health Hub.

In the area of research, it offers sequencing services in collaboration with BitGenetic, genomic data analysis, variant prioritization and in the area of prevention through the application of an algorithm for the identification of polygenic risk or PRS (Polygenic Risk Score) of common diseases using UKBiobank data and in the identification of risk biomarkers associated with drug response, including dose adjustment and potential adverse effects through pharmacogenetics (PGx), in order to provide a clinical recommendation for those drugs where genetic testing is recommended.

ADNTRO has been selected as one of the 10 most important Biotech companies of 2022 by Life Sciences Review.

Partners